---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-24-000110"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2024-08-29T23:59:59+00:00"
generated_at: "2026-05-31T06:59:49.020254+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BeiGene reports H1 2024 R&D expenses by product; total R&D up 10% YoY to $915M

## Summary
- Zanubrutinib R&D expense $62.9M in H1 2024, down 22% from $81.1M in H1 2023.
- Tislelizumab R&D expense $34.5M in H1 2024, down 27% from $47.0M in H1 2023.
- Bcl-2 (BGB-11417) R&D expense $38.6M in H1 2024, up 120% from $17.5M in H1 2023.
- Total R&D expense $915.1M in H1 2024 vs $831.3M in H1 2023, +10.1% YoY.
- R&D collaboration projects $82.5M in H1 2024, up from $23.3M in H1 2023.

## SEC filing metadata
- accession: 0001651308-24-000110
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2024-08-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000110/0001651308-24-000110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000110/bgne-20240829.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-24-000110
- JSON: https://secwatch.observer/filing/0001651308-24-000110.json
- Plain text: https://secwatch.observer/filing/0001651308-24-000110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.